# US 2021/0171432 A1 · Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171432 A1
- Document ID: US20210171432A1
- Status: Published application
- Kind: A1
- Application number: 17/110,236
- Filed: 2020-12-02
- Published: 2021-06-10
- Earliest claimed: 2016-06-07
- Assignees: The J. David Gladstone Institutes; The Regents of the University of California; Ithaca College
- Applicants: The J. David Gladstone Institutes; The Regents of the University of California; Ithaca College
- Inventors: Eric Verdin; Scott Michael Ulrich; John C. Newman
- Web page: https://patentgrep.com/patent/US20210171432A1

## CPC

- C07C 69/34: Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- A23L 33/12: Fatty acids or derivatives thereof
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- G02B 1/04: made of organic materials, e.g. plastics (G02B1/08 takes precedence)
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2200/322: having an effect on the health of the nervous system or on mental function
- A23V 2250/54: Proteins
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G02B: OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Aspects of the present disclosure include fatty acid β-hydroxyester compounds (e.g., fatty acid esters of β-hydroxybutyrate), fatty acid esters of butanediol, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions having one or more fatty acid β-hydroxyester compounds and/or one or more fatty acid esters of butanediol. Methods for treating a subject by administering one or more esters to the subject are also provided. Kits containing one or more of the subject esters are also described.

## Claims

### Claim at position 1

1-64. (canceled)

### Claim 65

A method of reducing epileptiform activity in the brain of a subject and/or treating in said subject one or more conditions selected from the group consisting of Alzheimer's disease, epilepsy, Parkinson's disease, heart failure, traumatic brain injury, stroke, hemorrhagic shock, acute lung injury after fluid resuscitation, acute kidney injury, myocardial infarction, myocardial ischemia, diabetes, glioblastoma multiforme, diabetic neuropathy, prostate cancer, amyotrophic lateral sclerosis, Huntington's disease, cutaneous T cell lymphoma, multiple myeloma, peripheral T cell lymphoma, HIV, and Niemann-Pick Type C disease said method comprising:
administering to said subject, a therapeutically effective amount of a compound of the Formula:
or a compound of Formula II:
or salts, solvates or hydrates thereof, wherein:
R4 is H or C(1-6) alkyl or substituted alkyl; and
R5 and R6 are independently unsubstituted or substituted C(4-30) alky.

### Claim 66 (depends on 65)

The method of claim 65, wherein the therapeutically effective amount is sufficient to reduce epileptiform activity in the brain of the subject.

### Claim 67 (depends on 66)

The method of claim 66, wherein said method comprises a method of reducing epileptiform activity in the brain of the subject.

### Claim 68 (depends on 65)

The method of claim 65, wherein said compound comprises a compound of Formula II.

### Claim 69 (depends on 68)

The method of claim 68, wherein R4 is an unsubstituted C(1-6) alkyl.

### Claim 70 (depends on 69)

The method of claim 69, wherein R4 is methyl.

### Claim 71 (depends on 68)

The method of claim 68, wherein R5 and R6 are independently unsubstituted C(6-18) alkyl.

### Claim 72 (depends on 68)

The method of claim 68, wherein R5 and R6 are independently unsubstituted C6 alkyl or independently unsubstituted C8 alkyl.

### Claim 73 (depends on 68)

The method of claim 68, wherein said compound is compound of Formula IIa:

### Claim 74 (depends on 68)

The method of claim 68, wherein said compound is a compound of Formula IIb:

### Claim 75 (depends on 68)

The method of claim 68, wherein said compound is compound having the formula:

### Claim 76 (depends on 65)

The method of claim 65, wherein said compound is compound having the formula:

### Claim 77 (depends on 65)

The method of claim 65, wherein said compound is compound having the formula:

### Claim 78 (depends on 65)

The method of claim 65, wherein said compound is compound having the formula:

### Claim 79 (depends on 65)

The method of claim 65, wherein said compound is compound having the formula:

### Claim 80 (depends on 65)

The method of claim 65, wherein said compound is administered as an oral preparation.

### Claim 81 (depends on 80)

The method of claim 80, wherein said oral preparation comprises a preservative and/or a flavoring agent.

### Claim 82 (depends on 81)

The method of claim 81, wherein said oral preparation comprises water.

### Claim 83 (depends on 82)

The method of claim 82, wherein said oral preparation comprises a syrup or an elixir.

### Claim 84 (depends on 82)

The oral preparation of claim 82, wherein said oral preparation comprises a suspension.

### Claim 85 (depends on 81)

The oral preparation of claim 81, wherein said oral preparation comprises a binder.

### Claim 86 (depends on 85)

The oral preparation of claim 85, wherein said oral preparation comprises a binder selected from the group consisting of cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, poly(ethylene glycol), sucrose, and starch.

### Claim 87 (depends on 81)

The oral preparation of claim 81, wherein said oral preparation comprises a flavoring agent.

### Claim 88 (depends on 87)

The oral preparation of claim 87, wherein said oral preparation comprises a flavoring agent selected from the group consisting of citric acid, menthol, glycine, and orange powder.

### Claim 89 (depends on 81)

The oral preparation of claim 81, wherein said oral preparation comprises a preservative.

### Claim 90 (depends on 89)

The oral preparation of claim 89, wherein said oral preparation comprises a preservative selected from the group consisting of sodium benzoate, sodium bisulfate, methylparaben, and propylparaben.

### Claim 91 (depends on 65)

The method of claim 65, wherein compound is administered as a food supplemented with said compound(s).

### Claim 92 (depends on 91)

The food supplement of claim 91, wherein said food comprises one or more additional components of a ketogenic diet.
